Chris Herring

Dr Chris Herring is the VP of Discovery Research at Adaptimmune where he leads early-stage discovery groups for new targets, TCRs, next-generation T-cells and research tools.

Prior to Adaptimmune, Chris was in the leadership team for GSK’s Cell & Gene Therapy Discovery Research group, leading T-cell engineering and AAV based gene therapy projects. Previously at GSK and Domantis he headed groups and project teams within Biopharm Discovery working on areas including domain antibodies, bispecific mAbs and half-life extension technologies in oncology, immuno-inflammation and enteroendocrine settings.

He holds a PhD in Oncology, specialising in DNA repair, from the Paterson Institute for Cancer Research in the University of Manchester, and a BSc (Hons) Biochemistry from the University of Surrey, UK.